Can a non‑fasting total cholesterol test be used for screening, and how should the results be interpreted?

Non-Fasting Total Cholesterol for Screening

Non-fasting total cholesterol testing is acceptable and effective for initial lipid screening in most adults and children, as total cholesterol levels do not vary appreciably with eating. 1

When Non-Fasting Testing is Appropriate

Non-fasting lipid panels are now widely endorsed for routine screening because:

• Total cholesterol and HDL-C remain stable regardless of fasting status, with variations of less than 2% across fasting durations 2
• Cardiovascular risk prediction is equivalent between fasting and non-fasting samples 3, 4
• Patient compliance improves significantly by eliminating the burden of fasting requirements 2, 5
• Laboratory efficiency increases by avoiding morning-only testing bottlenecks 2

The most recent Canadian guidelines (2021-2022) explicitly recommend non-fasting lipid testing as the preferred initial screening approach 5, 6. The 2019 ACC/AHA guidelines similarly state that either fasting or non-fasting samples are effective for estimating ASCVD risk and documenting baseline LDL-C 4.

How to Interpret Non-Fasting Results

For Total Cholesterol:

Use standard cutoffs without adjustment 1:

• Acceptable: <170 mg/dL (children/adolescents) or context-dependent for adults
• Borderline: 170-199 mg/dL (children/adolescents)
• High: ≥200 mg/dL (children/adolescents)

Critical Caveat - Triglycerides:

If non-fasting triglycerides are >150 mg/dL (>1.5 mmol/L), you must obtain a fasting lipid panel 5, 6. This is essential because:

• Triglycerides can be up to 20-25% higher in non-fasting samples 7
• Elevated triglycerides invalidate the Friedewald equation for calculating LDL-C 8, 4
• Non-fasting triglycerides >200 mg/dL (>2.0 mmol/L) are acceptable, but >400 mg/dL (>4.5 mmol/L) requires fasting confirmation 4, 6

When Fasting IS Required

Obtain fasting lipids in these specific situations:

1. Initial non-fasting triglycerides >150 mg/dL - to accurately calculate LDL-C 5, 6
2. Suspected genetic dyslipidemia or family history of premature ASCVD - for comprehensive phenotyping 3, 4
3. Monitoring patients on LDL-lowering therapy when triglycerides are elevated 5
4. Severe hypertriglyceridemia (>400-500 mg/dL) - to assess for genetic disorders 1
5. Very low LDL-C levels (<70 mg/dL) where precision matters for treatment decisions 4

Key Limitations of Non-Fasting Screening

Non-fasting samples may miss isolated low HDL-C 1. If total cholesterol is elevated above 170 mg/dL on non-fasting testing, verify with a fasting lipid profile to capture the complete lipid phenotype, including HDL-C and calculated LDL-C 1.

Practical Algorithm

1. Initial screening: Non-fasting total cholesterol, HDL-C, and triglycerides 5, 6
2. If triglycerides ≤150 mg/dL: Results are reliable; proceed with risk assessment
3. If triglycerides >150 mg/dL OR total cholesterol >170 mg/dL: Repeat with fasting lipid panel 1, 5
4. For treatment monitoring: Use non-HDL-C or ApoB rather than LDL-C when triglycerides are elevated 6

The 2020 Endocrine Society guidelines confirm that non-fasting samples can be obtained for lipoprotein(a) measurement as well 3. The shift toward non-fasting testing represents a pragmatic evolution in lipid screening that maintains diagnostic accuracy while removing barriers to cardiovascular risk assessment 2, 9, 10.